Company profile
Biocept, Inc.
OTC: BIOCQ · Healthcare · Medical - Diagnostics & Research
#521 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 33GM —SS 37
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ market scale, return on equity
Methodology →Revenue TTM
-$8.0M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$32.1M
Employees
50
as of 2026-08-03
Market cap
$263
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$25.9M$25.9M2022
Net income-$32.1M-$32.1M2022
Operating income-$32.0M-$32.0M2022
Total assets$30.9M$30.9M2022
Liabilities$22.0M$22.0M2022
Equity$8.9M$8.9M2022
Revenue trend
FY2019 – FY2022 · USD
FY19
FY19
FY19
FY19
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Biocept, Inc.’s revenue?
Biocept, Inc. booked $25.9M in FY2022 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -124.1% net margin.
Peers · Healthcare
Celularity Inc.31DNeurobiological Technologies, Inc.——Synovics Pharmaceuticals, Inc.——Gelesis Holdings, Inc.——Avant Brands Inc.59CEntrada Therapeutics, Inc.46DNeighbors
San Diego →Key facts
CEOSoon Kap Hahn
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSan Diego, CA
ExchangeOTC: BIOCQ
Employees50
IPO date2014-02-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.